- Home
- ZTR vs VYGR Comparison
ZTR vs VYGR Comparison
Compare ZTR & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- VYGR
- Stock Information
- Founded
- ZTR 1988
- VYGR 2013
- Country
- ZTR Australia
- VYGR United States
- Employees
- ZTR N/A
- VYGR N/A
- Industry
- ZTR Investment Managers
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- VYGR Health Care
- Exchange
- ZTR Nasdaq
- VYGR Nasdaq
- Market Cap
- ZTR 368.5M
- VYGR 297.7M
- IPO Year
- ZTR N/A
- VYGR 2015
- Fundamental
- Price
- ZTR $5.97
- VYGR $5.52
- Analyst Decision
- ZTR
- VYGR Strong Buy
- Analyst Count
- ZTR 0
- VYGR 9
- Target Price
- ZTR N/A
- VYGR $15.53
- AVG Volume (30 Days)
- ZTR 219.4K
- VYGR 338.7K
- Earning Date
- ZTR 01-01-0001
- VYGR 02-26-2025
- Dividend Yield
- ZTR 12.09%
- VYGR N/A
- EPS Growth
- ZTR N/A
- VYGR N/A
- EPS
- ZTR N/A
- VYGR 0.47
- Revenue
- ZTR N/A
- VYGR $163,784,000.00
- Revenue This Year
- ZTR N/A
- VYGR N/A
- Revenue Next Year
- ZTR N/A
- VYGR N/A
- P/E Ratio
- ZTR N/A
- VYGR $11.78
- Revenue Growth
- ZTR N/A
- VYGR 3.40
- 52 Week Low
- ZTR $4.50
- VYGR $4.99
- 52 Week High
- ZTR $6.60
- VYGR $10.66
- Technical
- Relative Strength Index (RSI)
- ZTR 53.97
- VYGR 41.99
- Support Level
- ZTR $5.91
- VYGR $5.32
- Resistance Level
- ZTR $6.02
- VYGR $5.76
- Average True Range (ATR)
- ZTR 0.07
- VYGR 0.28
- MACD
- ZTR 0.01
- VYGR 0.03
- Stochastic Oscillator
- ZTR 73.53
- VYGR 35.05
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective is capital appreciation, with current income as a secondary objective through a balance of equity and fixed income investments. It invests in operators of infrastructure in the communications, utility, energy, and transportation industries.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.